Story perspectives

Moderna Stock Plummets Amid New Vaccine Controversy

12/2/2025

Summary

Story summary

Moderna's stock fell about 7% after FDA official Vinay Prasad linked COVID-19 vaccines to at least 10 child deaths.
The FDA plans stricter testing requirements for vaccine approvals, especially pneumococcal vaccines.
Prasad's memo draws criticism for its inflammatory tone and lack of supporting data.
Analysts warn new restrictions could further dampen vaccination rates.
The FDA's oversight approach shifts under Health and Human Services Secretary Robert F. Kennedy Jr.

History

Historical Context

The 1976 U.S. swine flu vaccination campaign, initiated by President Gerald Ford, led to over 500 cases of Guillain-Barré syndrome, resulting in public distrust and the campaign's cancellation after 24% vaccination coverage. This historical episode parallels current concerns about COVID-19 vaccines, as FDA official Vinay Prasad raises safety issues, highlighting ongoing tensions between vaccine safety and public health initiatives.

1 of 2

Story summary

Moderna's stock fell about 7% after FDA official Vinay Prasad linked COVID-19 vaccines to at least 10 child deaths.
The FDA plans stricter testing requirements for vaccine approvals, especially pneumococcal vaccines.
Prasad's memo draws criticism for its inflammatory tone and lack of supporting data.
Analysts warn new restrictions could further dampen vaccination rates.
The FDA's oversight approach shifts under Health and Human Services Secretary Robert F. Kennedy Jr.

1 / 2